Lixte Biotechnology Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Geordan G. Pursglove
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 680 East Colorado Boulevard Pasadena CA United States of America 91101
- IPO Date
- Oct 25, 2007
- CIK
- 0001335105
- Website
- lixte.com
- Similar Companies
- Business
- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing protein phosphatase 2A (PP2A) inhibitors to enhance the efficacy of chemotherapy and immunotherapy for cancer treatment. The company focuses on its lead candidate LB-100, a proprietary PP2A inhibitor that promotes neoantigen production, cytokine release, T-cell proliferation, and disruption of cancer cell DNA repair mechanisms; it is advancing in multiple Phase 1b/2 clinical trials for solid tumors including ovarian clear cell carcinoma in combination with GSK's dostarlimab, metastatic colon cancer with Roche's atezolizumab, and advanced soft tissue sarcoma. Lixte Biotechnology operates primarily in the United States, conducting trials at leading institutions such as MD Anderson Cancer Center and the Netherlands Cancer Institute. Founded in 2005 and headquartered in Boca Raton, Florida, the company targets unmet needs in oncology with a comprehensive patent portfolio covering its novel approach, which has no direct competitors. In November 2025, Lixte Biotechnology acquired Liora Technologies' proprietary proton therapy platform, the LiGHT system, marking its entry into radiotherapy and complementing its pharmaceutical pipeline with plans for treatment centers and recurring revenue. Recent developments include validation of LB-100's approach in a July 2025 Nature publication and presentations at investor conferences, with preliminary Phase 1b/2 efficacy data anticipated in late 2025.
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
Powell Max Limited Successfully Repositions for Its Next Phase of Growth
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
Lixte Biotechnology (NASDAQ:LIXT) Trading Up 0.5% – Here’s Why
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers
LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans